PH12022552743A1 - Feline antibody variants - Google Patents
Feline antibody variantsInfo
- Publication number
- PH12022552743A1 PH12022552743A1 PH1/2022/552743A PH12022552743A PH12022552743A1 PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1 PH 12022552743 A PH12022552743 A PH 12022552743A PH 12022552743 A1 PH12022552743 A1 PH 12022552743A1
- Authority
- PH
- Philippines
- Prior art keywords
- antibody variants
- feline antibody
- feline
- relates
- variants
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063011491P | 2020-04-17 | 2020-04-17 | |
| PCT/US2021/027839 WO2021212084A1 (en) | 2020-04-17 | 2021-04-16 | Feline antibody variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12022552743A1 true PH12022552743A1 (en) | 2024-03-25 |
Family
ID=75870744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2022/552743A PH12022552743A1 (en) | 2020-04-17 | 2021-04-16 | Feline antibody variants |
Country Status (17)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018318440A1 (en) | 2017-08-15 | 2020-02-13 | Kindred Biosciences, Inc. | IgG Fc variants for veterinary use |
| CN120005022A (zh) | 2019-01-03 | 2025-05-16 | 因外泰克斯公司 | 用于增加治疗剂在犬中的半衰期的组合物及使用方法 |
| JP7832123B2 (ja) | 2020-05-11 | 2026-03-17 | インベテックス インコーポレイテッド | 治療薬のイヌにおける半減期を増加させるための組成物及びその使用方法 |
| EP4166574A4 (en) * | 2020-06-10 | 2025-01-15 | Bica Therapeutics Inc. | FUSION PROTEIN WITH ERYTHROPOIETIN POLYPEPTIDE |
| CN116096741B (zh) | 2020-07-10 | 2024-10-18 | 因外泰克斯公司 | 用于延长治疗剂在猫科动物中的半衰期的组合物和使用方法 |
| IL301414A (en) * | 2020-09-29 | 2023-05-01 | Zoetis Services Llc | Feline antibody variants |
| WO2025166165A1 (en) * | 2024-02-01 | 2025-08-07 | Zoetis Services, Llc | Compositions and methods for modifying antibody effector functions |
| WO2026136223A1 (en) * | 2024-12-19 | 2026-06-25 | Zoetis Services Llc | Compositions and methods for improving feline antibody functions |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6284471B1 (en) | 1991-03-18 | 2001-09-04 | New York University Medical Center | Anti-TNFa antibodies and assays employing anti-TNFa antibodies |
| US5698762A (en) | 1994-12-09 | 1997-12-16 | Dauerman; Leonard | Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons |
| US20030031671A1 (en) | 2001-08-01 | 2003-02-13 | Sydney Welt | Methods of treating colon cancer utilizing tumor-specific antibodies |
| CA2577133A1 (en) | 2004-08-19 | 2006-03-23 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US9200079B2 (en) | 2004-11-12 | 2015-12-01 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8546543B2 (en) | 2004-11-12 | 2013-10-01 | Xencor, Inc. | Fc variants that extend antibody half-life |
| KR101616758B1 (ko) * | 2007-12-26 | 2016-04-29 | 젠코어 인코포레이티드 | FcRn에 대한 변경된 결합성을 갖는 Fc 변이체 |
| ES2665954T3 (es) | 2010-08-19 | 2018-04-30 | Zoetis Belgium S.A. | Anticuerpos anti-NGF y su uso |
| US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
| US10093731B2 (en) * | 2017-02-24 | 2018-10-09 | Kindred Biosciences, Inc. | Anti-IL31 antibodies for veterinary use |
| EP3866842A4 (en) * | 2018-10-18 | 2022-07-13 | Kindred Biosciences, Inc. | FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE |
| WO2020116560A1 (ja) * | 2018-12-05 | 2020-06-11 | 株式会社バイカ・セラピュティクス | 抗体のFc領域改変体 |
-
2021
- 2021-04-16 EP EP21724443.3A patent/EP4136109A1/en active Pending
- 2021-04-16 CN CN202180028968.3A patent/CN115667300A/zh active Pending
- 2021-04-16 US US17/918,860 patent/US20240067730A1/en active Pending
- 2021-04-16 PH PH1/2022/552743A patent/PH12022552743A1/en unknown
- 2021-04-16 WO PCT/US2021/027839 patent/WO2021212084A1/en not_active Ceased
- 2021-04-16 KR KR1020227035858A patent/KR20230005158A/ko active Pending
- 2021-04-16 MX MX2022012793A patent/MX2022012793A/es unknown
- 2021-04-16 CA CA3176434A patent/CA3176434A1/en active Pending
- 2021-04-16 AU AU2021257355A patent/AU2021257355A1/en active Pending
- 2021-04-16 PE PE2022002416A patent/PE20230348A1/es unknown
- 2021-04-16 JP JP2022562646A patent/JP2023522030A/ja active Pending
- 2021-04-16 IL IL297290A patent/IL297290A/en unknown
- 2021-04-16 BR BR112022020631A patent/BR112022020631A2/pt unknown
- 2021-04-19 TW TW110113948A patent/TW202204404A/zh unknown
-
2022
- 2022-10-17 EC ECSENADI202280858A patent/ECSP22080858A/es unknown
- 2022-10-17 CL CL2022002856A patent/CL2022002856A1/es unknown
- 2022-10-18 CO CONC2022/0014684A patent/CO2022014684A2/es unknown
-
2023
- 2023-11-13 CL CL2023003376A patent/CL2023003376A1/es unknown
-
2024
- 2024-04-19 US US18/640,470 patent/US20250026834A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4136109A1 (en) | 2023-02-22 |
| CA3176434A1 (en) | 2021-10-21 |
| US20240067730A1 (en) | 2024-02-29 |
| TW202204404A (zh) | 2022-02-01 |
| CL2023003376A1 (es) | 2024-04-19 |
| PE20230348A1 (es) | 2023-03-02 |
| CO2022014684A2 (es) | 2022-11-08 |
| CL2022002856A1 (es) | 2023-06-02 |
| BR112022020631A2 (pt) | 2022-11-29 |
| US20250026834A1 (en) | 2025-01-23 |
| MX2022012793A (es) | 2022-11-07 |
| ECSP22080858A (es) | 2023-01-31 |
| WO2021212084A1 (en) | 2021-10-21 |
| KR20230005158A (ko) | 2023-01-09 |
| CN115667300A (zh) | 2023-01-31 |
| IL297290A (en) | 2022-12-01 |
| AU2021257355A1 (en) | 2022-11-03 |
| JP2023522030A (ja) | 2023-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012793A (es) | Variantes de anticuerpos felinos. | |
| PH12022552742A1 (en) | Canine antibody variants | |
| MX2023008785A (es) | Mutaciones en regiones constantes de anticuerpos caninos. | |
| WO2022067233A3 (en) | Canine antibody variants | |
| MX2023003694A (es) | Variantes de anticuerpos felinos. | |
| MX2023003397A (es) | Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15. | |
| WO2019224716A8 (en) | Antibodies specific for gucy2c and uses thereof | |
| PH12023550161A1 (en) | Pharmaceutical composition and use thereof | |
| MA53356B1 (fr) | Formulations sous-cutanées d'anticorps anti-cd38 et leurs utilisations | |
| JOP20220161A1 (ar) | جسم مضاد لـ lilrb1 واستخداماته | |
| MX2023005896A (es) | Variantes de anticuerpos bovinos. | |
| CO2023007829A2 (es) | Mutaciones en regiones constantes de anticuerpos felinos | |
| MX2022011077A (es) | Variantes de transglutaminasa. | |
| ZA202106807B (en) | Antibodies having specificity for btn2 and uses thereof | |
| MX2023009549A (es) | Compuestos y metodos para prolongar la vida media de biomoleculas. | |
| MX2025001433A (es) | Mutantes de anticuerpos bovinos | |
| MX2025002522A (es) | Mutantes de anticuerpos porcinos | |
| CO2018006345A2 (es) | Almidón estabilizado | |
| MX2024013189A (es) | Anticuerpos anti-ly6e, inmunoconjugados y usos de estos | |
| FR3035664B1 (fr) | Utilisation de cysteine endoprotease pour diminuer le trouble de boissons | |
| UA90682C2 (en) | Variant fc regions |